DiaSorin Hepatitis B Tests Need Clearer Indication Of "High-Risk" Population
This article was originally published in The Gray Sheet
Executive Summary
DiaSorin needs to distinguish between specific subgroups of high-risk patient populations in labeling of its ETI Plus line of in vitro diagnostic hepatitis B serological marker assays, FDA's Microbiology Devices Advisory Panel agreed in recommending six assays for approval at a Jan. 20 meeting in Rockville, Maryland.
You may also be interested in...
Final HCV Guidance Should Allow For Sample Bank Correlation Studies - HIMA
The "least burdensome" approach to resolving discrepant patient information in hepatitis C assay clinical studies - allowing use of sample bank correlation studies - should be explicitly stated in FDA's final guidance, the Health Industry Manufacturers Association says in comments to FDA.
Final HCV Guidance Should Allow For Sample Bank Correlation Studies - HIMA
The "least burdensome" approach to resolving discrepant patient information in hepatitis C assay clinical studies - allowing use of sample bank correlation studies - should be explicitly stated in FDA's final guidance, the Health Industry Manufacturers Association says in comments to FDA.
In-Vitro Diagnostics Should Be Eligible For Third-Party Review - Industry
FDA should identify more in-vitro diagnostics for inclusion in the agency's "Accredited Persons" third-party premarket review program, DiaSorin VP Regulatory Affairs and Quality Systems, Judith Smith recommended.